TY - JOUR
T1 - Hematocrit and the risk of cardiovascular disease in a Japanese community
T2 - The Hisayama Study
AU - Gotoh, Seiji
AU - Hata, Jun
AU - Ninomiya, Toshiharu
AU - Hirakawa, Yoichiro
AU - Nagata, Masaharu
AU - Mukai, Naoko
AU - Fukuhara, Masayo
AU - Ikeda, Fumie
AU - Ago, Tetsuro
AU - Kitazono, Takanari
AU - Kiyohara, Yutaka
N1 - Funding Information:
This study was supported in part by Grants-in-Aid for Scientific Research on Innovative Areas (22116010) and for Scientific Research (A) (25253048 and 22240073) and (C) (24590797, 24590796, 25460758, 26350895, and 26460748) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, by a Core Research for Evolutionary Science and Technology (CREST) grant ( 13417915 ) from the Japan Science and Technology Agency, and by Health and Labour Sciences Research Grants of the Ministry of Health, Labour and Welfare of Japan ( H22-Junkankitou [Seishuu]-Ippan-005 , H25-Junkankitou [Seishuu]-Ippan-005 , H25-Junkankitou [Seishuu]-Ippan-009 , H25-Junkankitou [Seishuu]-Sitei-022 , H26-Junkankitou [Seisaku]-Ippan-001 , and H25-Ninchisho-Ippan-004 ).
Publisher Copyright:
© 2015 Elsevier Ireland Ltd.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Objectives: The association between hematocrit levels and the risk of cardiovascular disease (CVD) has been reported inconsistently. We aimed to investigate the association of hematocrit levels with the development of stroke and coronary heart disease (CHD) in a general Japanese population. Methods: A total of 2585 community-dwelling Japanese individuals aged 40 years or older in 1988 were followed up for 19 years. These subjects were divided into four groups according to the sex-specific quartiles of hematocrit at baseline. Results: During the follow-up, 301 subjects developed stroke (210 ischemic and 91 hemorrhagic) and 187 developed CHD. The risk of ischemic stroke was higher in both the lowest (Q1: men, ≤44.7%; women, ≤39.3%) and the highest (Q4: men, ≥49.7%; women, ≥43.8%) quartiles than in the third quartile (Q3: men, 47.1%-49.6%; women, 41.7%-43.7%) used as a reference (multivariable-adjusted hazard ratios [95% confidence intervals]: Q1, 1.55 [0.99-2.43]; Q2, 1.44 [0.93-2.23]; Q3, 1.00; and Q4, 1.62 [1.06-2.50]; P=0.86 for trend). In contrast, hematocrit levels and the risk of hemorrhagic stroke showed a linear inverse association (Q1, 1.91 [1.03-3.54]; Q2, 1.26 [0.68-2.34]; Q3, 1.00; and Q4, 0.81 [0.41-1.61]; P=0.009 for trend). The risk of CHD increased significantly in Q4 (Q1, 1.13 [0.71-1.80]; Q2, 1.08 [0.69-1.71]; Q3, 1.00; and Q4, 1.60 [1.04-2.46]; P=0.13 for trend). Conclusions: Our findings suggest that both elevated and decreased hematocrit levels are associated with an increased risk of CVD, but the influence of hematocrit is different among subtypes of CVD.
AB - Objectives: The association between hematocrit levels and the risk of cardiovascular disease (CVD) has been reported inconsistently. We aimed to investigate the association of hematocrit levels with the development of stroke and coronary heart disease (CHD) in a general Japanese population. Methods: A total of 2585 community-dwelling Japanese individuals aged 40 years or older in 1988 were followed up for 19 years. These subjects were divided into four groups according to the sex-specific quartiles of hematocrit at baseline. Results: During the follow-up, 301 subjects developed stroke (210 ischemic and 91 hemorrhagic) and 187 developed CHD. The risk of ischemic stroke was higher in both the lowest (Q1: men, ≤44.7%; women, ≤39.3%) and the highest (Q4: men, ≥49.7%; women, ≥43.8%) quartiles than in the third quartile (Q3: men, 47.1%-49.6%; women, 41.7%-43.7%) used as a reference (multivariable-adjusted hazard ratios [95% confidence intervals]: Q1, 1.55 [0.99-2.43]; Q2, 1.44 [0.93-2.23]; Q3, 1.00; and Q4, 1.62 [1.06-2.50]; P=0.86 for trend). In contrast, hematocrit levels and the risk of hemorrhagic stroke showed a linear inverse association (Q1, 1.91 [1.03-3.54]; Q2, 1.26 [0.68-2.34]; Q3, 1.00; and Q4, 0.81 [0.41-1.61]; P=0.009 for trend). The risk of CHD increased significantly in Q4 (Q1, 1.13 [0.71-1.80]; Q2, 1.08 [0.69-1.71]; Q3, 1.00; and Q4, 1.60 [1.04-2.46]; P=0.13 for trend). Conclusions: Our findings suggest that both elevated and decreased hematocrit levels are associated with an increased risk of CVD, but the influence of hematocrit is different among subtypes of CVD.
UR - http://www.scopus.com/inward/record.url?scp=84937239635&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937239635&partnerID=8YFLogxK
U2 - 10.1016/j.atherosclerosis.2015.07.014
DO - 10.1016/j.atherosclerosis.2015.07.014
M3 - Article
C2 - 26204496
AN - SCOPUS:84937239635
SN - 0021-9150
VL - 242
SP - 199
EP - 204
JO - Atherosclerosis
JF - Atherosclerosis
IS - 1
ER -